Blue Owl Capital Holdings LP Makes New $3.92 Million Investment in Aquestive Therapeutics, Inc. $AQST

Key Points

• Blue Owl Capital Holdings initiated a $3.92 million position in Aquestive Therapeutics, purchasing 942,932 shares, or approximately 0.75% of the company. Other institutional investors also increased their stakes, bringing institutional ownership to 32.45%.
• Aquestive reported a quarterly loss of $0.18 per share, missing the $0.10 consensus estimate, although revenue of $13.82 million exceeded expectations. Shares opened at $4.49, down 2.2%, with a market capitalization of about $563.6 million.
• Analyst sentiment remains mixed but leans positive: the stock has a consensus “Buy” rating and an average price target of $8.50, while one director sold 25,000 shares for $125,500 under a pre-arranged Rule 10b5-1 plan.

Blue Owl Capital Holdings LP bought a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 942,932 shares of the company's stock, valued at approximately $3,923,000. Aquestive Therapeutics accounts for approximately 0.6% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 27th largest holding. Blue Owl Capital Holdings LP owned 0.75% of Aquestive Therapeutics as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the business. AQR Capital Management LLC lifted its holdings in Aquestive Therapeutics by 12.2% in the first quarter. AQR Capital Management LLC now owns 129,019 shares of the company's stock valued at $374,000 after buying an additional 14,025 shares during the period. Geode Capital Management LLC lifted its stake in shares of Aquestive Therapeutics by 16.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company's stock valued at $6,545,000 after purchasing an additional 276,295 shares during the period. Creative Planning boosted its position in shares of Aquestive Therapeutics by 15.3% in the 2nd quarter. Creative Planning now owns 98,751 shares of the company's stock worth $327,000 after purchasing an additional 13,130 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Aquestive Therapeutics by 46.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 435,972 shares of the company's stock worth $1,443,000 after purchasing an additional 137,956 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Aquestive Therapeutics by 35.0% during the second quarter. Rhumbline Advisers now owns 140,872 shares of the company's stock worth $466,000 after purchasing an additional 36,509 shares during the period. Institutional investors own 32.45% of the company's stock.

Insider Transactions at Aquestive Therapeutics

In related news, Director Julie Krop sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the sale, the director directly owned 25,000 shares of the company's stock, valued at approximately $125,500. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company's stock.

Aquestive Therapeutics Trading Down 2.2%

Shares of Aquestive Therapeutics stock opened at $4.49 on Friday. The stock's fifty day simple moving average is $4.17 and its 200 day simple moving average is $4.12. The company has a market capitalization of $563.55 million, a PE ratio of -6.91 and a beta of 1.49. Aquestive Therapeutics, Inc. has a 12 month low of $2.93 and a 12 month high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million during the quarter, compared to the consensus estimate of $11.42 million. Analysts predict that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on AQST shares. Oppenheimer started coverage on Aquestive Therapeutics in a research note on Friday, April 24th. They issued an "outperform" rating and a $8.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Aquestive Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded shares of Aquestive Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Aquestive Therapeutics has a consensus rating of "Buy" and an average target price of $8.50.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.

Want to see what other hedge funds are holding AQST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source